New Alzheimer’s Drug Shows Promise by Repairing DNA Damage and Reducing Brain Inflammation

An experimental drug originally developed to treat spinal cord injuries could offer a promising new approach to fighting Alzheimer’s disease. Researchers at King’s College London have found that the drug, known as KCL-286, may help repair DNA damage, reduce brain inflammation, and address multiple biological changes associated with the disease.

The findings, based on experiments involving mice with Alzheimer’s-like disease, suggest that targeting several harmful processes simultaneously could provide a broader treatment strategy than approaches that primarily focus on removing toxic proteins from the brain.

One of the drug’s potential advantages is that it has already completed Phase 1 human safety and tolerability trials during its earlier development. This could help accelerate its progress through the drug development process. However, its effectiveness against Alzheimer’s disease in humans has not yet been established.

“KCL-286 is a first-in-class, orally bioavailable small molecule that has already successfully cleared Phase 1 human safety and tolerability trials. This will dramatically cut down the traditional multi-year timeline required for new drug development,” commented Professor Jonathan Corcoran, Professor of Neuroscience at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London.

KCL-286 is an orally administered small-molecule drug, which means it could potentially be taken as a tablet rather than requiring injections or intravenous infusions. Its existing human safety data also offers researchers a potential advantage as they explore its therapeutic applications.

Why Alzheimer’s Disease Is Difficult to Treat

Alzheimer’s disease is a progressive neurological condition involving several interconnected biological changes in the brain. Two of its most widely recognised characteristics are the abnormal accumulation of amyloid-beta and tau proteins.

Amyloid-beta proteins can accumulate in the spaces between nerve cells, forming sticky deposits known as plaques. Meanwhile, abnormal tau proteins collect inside neurons, creating tangled structures that interfere with their normal functioning.

Over time, these changes disrupt communication between brain cells and contribute to the progressive loss of neurons. Since neurons play an essential role in transmitting information throughout the brain, their damage can gradually affect memory, thinking, and other cognitive abilities.

For years, much of Alzheimer’s drug development has concentrated on targeting amyloid-beta and tau. Although treatments designed to remove amyloid-beta have demonstrated modest but measurable clinical benefits, they do not address every biological process contributing to the disease.

This has encouraged scientists to investigate other mechanisms that may play a role in Alzheimer’s development, particularly DNA damage and inflammation in the brain. Both processes can emerge during the earlier stages of the disease, making them important potential targets for therapies intended to slow its progression.

How KCL-286 Could Help Protect the Brain

The King’s College London research explored whether KCL-286 could address some of these additional biological changes.

In the mouse model of Alzheimer’s disease, the experimental drug helped repair breaks in damaged DNA and reduced inflammation in the brain. These findings indicate that the compound may influence multiple disease-related processes rather than concentrating on a single biological target.

DNA damage is particularly important because neurons rely on the integrity of their genetic material to maintain normal cellular functions. When DNA repair mechanisms become impaired, accumulated damage can interfere with the health and survival of brain cells.

Similarly, persistent inflammation in the brain can contribute to an environment that damages neurons and potentially accelerates disease progression.

By addressing both DNA damage and inflammation, KCL-286 could offer a broader therapeutic strategy for Alzheimer’s disease. Researchers believe that targeting these processes early may be particularly valuable, as some of the underlying biological changes begin before more advanced symptoms become apparent.

“Our findings demonstrate that KCL-286 not only targets DNA damage but also reduces inflammation, two processes that occur very early in Alzheimer’s disease progression. This highlights its potential as a disease-modifying therapy rather than simply addressing symptoms,” said Dr. Maria Goncalves, who project-managed the drug development.

What This Could Mean for Future Alzheimer’s Treatments

One of the most encouraging aspects of KCL-286’s development is its previous completion of Phase 1 human safety and tolerability trials. Early-stage human trials generally assess whether an experimental drug is safe and tolerable, rather than establishing whether it can effectively treat a particular disease.

Since this initial stage has already been completed, researchers may be able to avoid repeating some of the preliminary safety assessments traditionally required when developing a new drug.

However, the promising findings in mice do not establish that KCL-286 will produce similar benefits in people living with Alzheimer’s disease. Further research and clinical trials will be necessary to determine its effectiveness, appropriate dosage, and long-term safety in this population.

Nevertheless, the findings highlight the potential of investigating biological mechanisms beyond amyloid-beta and tau. If future studies confirm its benefits in humans, KCL-286 could contribute to a new generation of Alzheimer’s treatments designed to address multiple aspects of the disease rather than targeting individual symptoms or protein deposits.